QIAGEN Gross Profit 2010-2023 | QGEN

QIAGEN annual/quarterly gross profit history and growth rate from 2010 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • QIAGEN gross profit for the quarter ending March 31, 2023 was $0.307B, a 25.9% decline year-over-year.
  • QIAGEN gross profit for the twelve months ending March 31, 2023 was $1.277B, a 14.59% decline year-over-year.
  • QIAGEN annual gross profit for 2022 was $1.385B, a 4.57% decline from 2021.
  • QIAGEN annual gross profit for 2021 was $1.451B, a 17.69% increase from 2020.
  • QIAGEN annual gross profit for 2020 was $1.233B, a 22.63% increase from 2019.
QIAGEN Annual Gross Profit
(Millions of US $)
2022 $1,385
2021 $1,451
2020 $1,233
2019 $1,005
2018 $1,001
2017 $923
2016 $845
2015 $827
2014 $865
2013 $815
2012 $824
2011 $750
2010 $716
2009 $667
QIAGEN Quarterly Gross Profit
(Millions of US $)
2023-03-31 $307
2022-12-31 $318
2022-09-30 $321
2022-06-30 $331
2022-03-31 $415
2021-12-31 $374
2021-09-30 $337
2021-06-30 $369
2021-03-31 $371
2020-12-31 $373
2020-09-30 $321
2020-06-30 $295
2020-03-31 $244
2019-12-31 $280
2019-09-30 $255
2019-06-30 $246
2019-03-31 $225
2018-12-31 $265
2018-09-30 $257
2018-06-30 $254
2018-03-31 $226
2017-12-31 $261
2017-09-30 $241
2017-06-30 $225
2017-03-31 $196
2016-12-31 $228
2016-09-30 $221
2016-06-30 $211
2016-03-31 $185
2015-12-31 $224
2015-09-30 $205
2015-06-30 $201
2015-03-31 $198
2014-12-31 $216
2014-09-30 $223
2014-06-30 $216
2014-03-31 $210
2013-12-31 $236
2013-09-30 $211
2013-06-30 $169
2013-03-31 $200
2012-12-31 $233
2012-09-30 $199
2012-06-30 $203
2012-03-31 $189
2011-12-31 $202
2011-09-30 $188
2011-06-30 $188
2011-03-31 $172
2010-12-31 $189
2010-09-30 $181
2010-06-30 $173
2010-03-31 $173
2009-12-31 $188
2009-09-30 $173
2009-06-30 $160
2009-03-31 $146
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.584B $2.142B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.942B 8.43
GSK (GSK) United Kingdom $69.839B 9.75
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
Ginkgo Bioworks Holdings (DNA) United States $3.379B 0.00
Arcus Biosciences (RCUS) United States $1.536B 0.00
Biohaven (BHVN) United States $1.482B 0.00
Emergent Biosolutions (EBS) United States $0.416B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.191B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00